Your browser doesn't support javascript.
loading
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Huemer, Florian; Weiss, Lukas; Faber, Viktoria; Neureiter, Daniel; Egle, Alexander; Geissler, Klaus; Voskova, Daniela; Zebisch, Armin; Burgstaller, Sonja; Pichler, Angelika; Stauder, Reinhard; Sperr, Wolfgang; Lang, Alois; Pfeilstöcker, Michael; Machherndl-Spandl, Sigrid; Stampfl, Margarete; Greil, Richard; Pleyer, Lisa.
Afiliação
  • Huemer F; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Muellner Hauptstraße 48, 5020, Salzburg, Austria.
  • Weiss L; Cancer Cluster Salzburg, Salzburg, Austria.
  • Faber V; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Muellner Hauptstraße 48, 5020, Salzburg, Austria.
  • Neureiter D; Cancer Cluster Salzburg, Salzburg, Austria.
  • Egle A; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Muellner Hauptstraße 48, 5020, Salzburg, Austria.
  • Geissler K; Cancer Cluster Salzburg, Salzburg, Austria.
  • Voskova D; Institute of Pathology, Paracelsus Medical University, Salzburg, Austria.
  • Zebisch A; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Muellner Hauptstraße 48, 5020, Salzburg, Austria.
  • Burgstaller S; Cancer Cluster Salzburg, Salzburg, Austria.
  • Pichler A; 5th Department of Medicine, Hospital Hietzing, Vienna, Austria.
  • Stauder R; Clinical Division of Internal Medicine 3­Hematology and Oncology, Kepler University Hospital, Linz, Austria.
  • Sperr W; Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Lang A; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Pfeilstöcker M; Department for Haematology and Oncology, LKH Hochsteiermark, Leoben, Austria.
  • Machherndl-Spandl S; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
  • Stampfl M; Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria.
  • Greil R; Department of Internal Medicine, Landeskrankenhaus Feldkirch, Feldkirch, Austria.
  • Pleyer L; 3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, Austria.
Wien Klin Wochenschr ; 130(3-4): 115-125, 2018 Feb.
Article em En | MEDLINE | ID: mdl-29383443

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mielomonocítica Crônica / Hidroxiureia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Wien Klin Wochenschr Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria País de publicação: Áustria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mielomonocítica Crônica / Hidroxiureia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Wien Klin Wochenschr Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria País de publicação: Áustria